Exclusive: Merck In Multiple Partnerships To Finance Hep C Treatment In India
This article was originally published in PharmAsia News
Executive Summary
In what could perhaps be the first such experiment in the Indian pharmaceutical industry, Merck’s Indian arm MSD India has linked up with a financial institution and is considering a national rollout of a funding plan that aims to expand the cost of hepatitis C treatment over several months, thereby easing the burden on needy patients. The bigger gain could mean that from just 3% of the population that get treated for the fatal disease the number could swell to roughly 45% of the population.